RNTX logo

REIN THERAPEUTICS INC

RNTXNASDAQ
🏆 #4302 by market capUS Equity
$0.79▲ $0.07 (+8.73%)
Market closed · at close
🔔
Track RNTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.7%
7d▲ 2.5%
14d▲ 13.0%
30d▲ 6.5%
ytd▼ 32.2%
1y▼ 31.0%
🏦Market Cap
$68M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
60
Fair

Trading Snapshot

Day Range
$0.79 – $0.80
52-Week Range
$0.69 – $2.18
Volume
$4.82B
Avg Volume
$4.80B
Shares Outstanding
85.5M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.59
Dividend Yield
—
Dilution (1yr)
+17.3%

Why Investors Own RNTX

  • ✓High-growth profile — revenue up +32.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RNTX logo

REIN THERAPEUTICS INC

RNTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −66.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −13.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.4M▲ +17.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▼ −$10M YoY
StockOtter · stockotter.space

About REIN THERAPEUTICS INC

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1.02
▲ +28.2% Upside
High Target$1.21
Low Target$0.83
Based on 21 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

REIN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift RNTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

REIN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.